Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia

Mohamed A Albekery, Ibrahim S Alhomoud, Khalid A Alamer, Ahmed A Alanazi, Abdulmohsen E Al Mulhem, Ahmed E Alnaim, Fahad M Almulhim, Abdulrahman S Almulhim · 2026

Read Real-world outcomes of Finerenone in patients with diabetic kidney disease in Saudi Arabia by Mohamed A Albekery, Ibrahim S Alhomoud, Khalid A Alamer, Ahmed A Alanazi, Abdulmohsen E Al Mulhem, Ahmed E Alnaim, Fahad M Almulhim, Abdulrahman S Almulhim (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0352861.txt.

Description

Mohamed Albekery and seven colleagues report real-world experience with the drug finerenone in Saudi Arabia in 2026. The drug treats diabetic kidney disease, a common complication of type 2 diabetes. Large trials showed it protects kidneys and the heart. Far less was known about how it performs in everyday Saudi clinics.

The team reviewed records of adults treated at a single centre. Sixty-seven patients met the study criteria. Changes over time were tracked for urine protein, kidney function, and blood potassium. Potassium matters because this drug class can push it too high. Mixed-effects models adjusted the trends for other patient factors. Studies like this test whether trial benefits survive contact with routine care, local diets, and ordinary prescribing habits.

Catalog record

CREATORMohamed A Albekery, Ibrahim S Alhomoud, Khalid A Alamer, Ahmed A Alanazi, Abdulmohsen E Al Mulhem, Ahmed E Alnaim, Fahad M Almulhim, Abdulrahman S Almulhim
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30702
LICENSECC_BY
RIGHTSCC BY
SOURCEPLOS

Source: https://doi.org/10.1371/journal.pone.0352861

Browse the full library · About the Tower of Babel